The Efficacy of Treatments to Improve Self-esteem
ConditionSelf Esteem
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorGGZ Noord-Holland-Noord
About this trial
The goal of this study is to examine the effectivity of two self-esteem interventions (COMET (Korrelboom) and CBT (De Neef)) in a general psychiatric population.
The main questions it aims to answer are:
* is there a difference between the two interventions in effectiveness on increasing self-esteem? * is there a difference between the two interventions in effect on levels of anxiety, depression and general mental health? * are found effects on levels of anxiety, depression and general mental health associated with changes in self-esteem? * is the ability to use imagination a moderator for outcomes in both conditions?
Participants are randomised over both conditions. At baseline (T0), end of treatment (T1) and follow-up at 6 months (T2) several outcome measures are conducted, such as RSES, DASS and MHC-SF.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
severe suicidality for which hospitalization or other forms of crisis care is necessary,
acute psychosis,
current manic episode,
current alcohol or drug abuse,
Trial design
Design model
Parallel
Treatments tested in this trial
COMET
Behavioralinformation already included in arm/group descriptions.
CBT
Behavioralinformation already included in arm/group descriptions.
Treatment groups
70 Participants
are divided into 2 treatment groupsGroup A: COMET (Korrelboom)Experimental treatment 1 intervention
Group B: CBT (De Neef)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Rosenberg self-esteem scale (RSES)
Rosenberg self-esteem scale assesses global selfesteem on a 10-item questionnaire, items to be answered on a 4-point Likert scale ranging from 0 (strongly agree) to 3 (strongly disagree). Total scores range from 0 up to 30, with higher scores indicating a higher global self-esteem.
Time frame
Baseline (T0), end of treatment (T1)(one week after the last intervention session), follow-up (T2 at 6 months)Secondary outcomes
1
Depression Anxiety Stress Scale (DASS)
Depression Anxiety Stress Scale is a 42-item questionnaire with items rated on a 4-point Likert scale, ranging from 0 (never) to 3 (definitely or most of the time). The DASS consists of three subscales of 14 items: Depression, Anxiety and Stress. Total scores on the subscales range from 0 up to 42, with higher scores indicating a higher levels of distress.
Time frame
Baseline (T0), end of treatment (T1)(one week after the last intervention session), follow-up (T2 at 6 months)2
Mental Health Continuum - Short Form (MHC-SF)
Mental Health Continuum - Short Form is a 14 item questionnaire with items to be rated on a 6-point Likert scale, ranging from 0 (never) to 5 (every day). Higher scores mean a better outcome. Total score intends to measure positive mental health as a distinct indicator of mental well-being. Three subscales are Emotional well-being (presence of positive feelings), Psychological well-being (positive functioning in individual life) and Social well-being (positive functioning in community life). Higher scores indicate more well-being.
Time frame
Baseline (T0), end of treatment (T1)(one week after the last intervention session), follow-up (T2 at 6 months)3
Plymouth Sensory Imagery Questionnaire (PsiQ-NL-35)
Plymouth Sensory Imagery Questionnaire is a 35 item questionnaire. It assesses mental imagery vividness on 5 items for 7 modalities (i.e., vision, sound, smell, taste, touch, bodily sensation and emotion). Each of the 7 modalities have a heading such as 'imagine the smell of…', followed by 5 items such as 'a rose' or 'burning wood'. Items are to be rated on a 11-point scale (0-10), ranging from 0 (no image at all) to 10 (as vivid as real life).
Time frame
Baseline (T0)Other outcomes
1
Demographics
Demographics
Time frame
Baseline (T0)2
DSM-5 classifications
Classifications according to the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
Time frame
Baseline (T0)3
Medication (type)
Type of medication
Time frame
Measured from start of treatment until end of treatment (T1)(one week after the last intervention session), and from end of treatment (T1)(one week after the last intervention session) until follow-up (T2 at 6 months)4
Medication (dose)
Dose of medication per type of medication
Time frame
Measured from start of treatment until end of treatment (T1)(one week after the last intervention session), and end of treatment (T1)(one week after the last intervention session) until follow-up (T2 at 6 months)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov